Landmark international study for Multiple Sclerosis
NUH is leading the UK delivery of the DELIVER-MS Study, a landmark trial spanning the UK and United States looking into disease modifying therapy (DMT) for Multiple Sclerosis (MS), a debilitating neurological disease.
DELIVER-MS is investigating whether early treatment with highly effective medication (DMT) improves the prognosis for people with MS.
How this study will help patients
The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies, but also to new therapies. This will help patients and their families to decide what is best for them as well as giving clarity for clinical teams.
For more information
The DELIVER-MS study is open for people with relapsing-remitting MS who have not previously received any DMT and are under the age of 55 years. Speak to your GP or your Clinical Team at NUH if you would like to be take part.
More information on the trial, which is supported by the Multiple Sclerosis Society in the UK, can be found at: https://deliver-ms.com/